

November 24, 2015



Second Sight to Present at Piper Jaffray 27th Annual Healthcare Conference

SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, announced today that Will McGuire, President and Chief Executive Officer, will present at the Piper Jaffray 27th Annual Healthcare Conference as follows:

Date: Wednesday, December 2, 2015

Time: 3:00 p.m. EST

Location: Lotte New York Palace Hotel, NYC

The presentation will be webcast live at the aforementioned time, and archived for 90 days thereafter, via the Company's website at www.secondsight.com, under the "Investors" Section.

About the Argus II® Retinal Prosthesis System

Second Sight's Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining viable cells inducing visual perception in individuals with severe to profound Retinitis Pigmentosa. The Argus II works by converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses are intended to stimulate the retina's remaining cells, resulting in the perception of patterns of light in the brain. The patient then learns to interpret these visual patterns, thereby regaining some visual function. The Argus II is the first artificial retina to receive widespread approval, and is offered at approved centers in Canada, France, Germany, Italy, Netherlands, Saudi Arabia, Spain, Switzerland, Turkey, United Kingdom, and the U.S.

About Second Sight

Second Sight's mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight has developed and manufactures the Argus® II Retinal Prosthesis System. Enrollment is underway in a trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. U.S. Headquarters are in Sylmar, CA, and European

Headquarters are in Lausanne, Switzerland. For more information, visit www.secondsight.com.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20151124005317/en/>

Investor Relations:

Institutional Investors

In-Site Communications, Inc.

Lisa Wilson, 212-452-2793

President

lwilson@insitecony.com

or

Individual Investors

MZ North America

Matt Hayden, 949-259-4896

Chairman

matt.hayden@mzgroup.us

Source: Second Sight Medical Products, Inc